Cadonilimab Combined with chemotherapy

Phase 2Small molecule

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Cadonilimab Combined with chemotherapy is one of 10 small molecule programs targeting Pleural Mesothelioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pleural MesotheliomaNot yet recruiting

Pleural MesotheliomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

10 competitors in Pleural Mesothelioma

#DrugCompanyPhaseTrials

Alimta

SShawn Eagle

Phase 3

6 2

Paraplatin

AAvyxa

Phase 3

3 3

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

1 4

Volrustomig

AstraZeneca

Phase 3

1 5

Keytruda

Merck & Co.

Phase 2

2 6

Ivonescimab Combined With Chemotherapy

SSun Yat-sen University

Phase 2

1 7

Anetumab Ravtansine

Bayer

Phase 2

1 8

Neoadjuvant Therapy 1

TTang-Du Hospital

Phase 2

1 9

Ga-FAPI-46 PET/CT

JJohn O. Prior

Phase 2

1 10

Cadonilimab Combined with chemotherapy

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Not yet recruiting

Pleural Mesothelioma

NCT06416930

Clinical

Trials by Indication[1]

Pleural Mesothelioma1 trial

Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma

Not yet recruiting·—·Phase 2·NCT06416930·59 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cadonilimab Combined with chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cadonilimab Combined with chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cadonilimab Combined with chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cancer Institute and Hospital, Chinese Academy of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Cadonilimab Combined with chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Pleural Mesothelioma1 trial

References

Drug Info

Quick Facts

Related News